<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226769</url>
  </required_header>
  <id_info>
    <org_study_id>OCUN-023</org_study_id>
    <nct_id>NCT03226769</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease</brief_title>
  <official_title>Prospective, Open-Label, Randomized, Proof of Concept Study Exploring Application of TrueTear™ for the Treatment of Meibomian Gland Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety and efficacy of TrueTear™ to standardized moist heat&#xD;
      compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Actual">December 12, 2017</completion_date>
  <primary_completion_date type="Actual">December 12, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Meibomian Gland Dysfunction (MGD) Impact Questionnaire Score</measure>
    <time_frame>Baseline (Day 0) to Day 30</time_frame>
    <description>MGD impact questionnaire includes 10 questions about the impacts a participant may experience associated with MGD. Participants were asked to rate how much they have been affected by MGD symptoms in past 7 days. Question/s (Qs) 1-6 (computer usage, reading, leisure activities, social activities, driving and outdoor activities) were rated on a scale of 1=no difficulty to 5=a lot of difficulty. Q7 (frequency of outdoor activities) was rated on scale of 1=never to 5=all the time. If participants did not experience a particular impact, they chose 0=NA for Qs 1-7. Q8 (time spent to take care of eyes) was rated on scale 0-4, where 0=no time at all to 4=a lot of time, Qs 9-10 (bothered with amount of time taking care of eyes and bothered by appearance) were rated on scale 0-4, with 0=not at all bothered to 4=very bothered. Higher scores represented greater impact. A negative change from Baseline indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in MGD Symptoms Questionnaire Score</measure>
    <time_frame>Baseline (Day 0) to Day 30</time_frame>
    <description>MGD symptom questionnaire included 11 questions about the symptoms the participant may experience associated with MGD. The participant was asked to rate how much they experienced certain MGD symptoms and the severity of the symptoms over the past 24 hours on a scale of 0 to 4, where 0 = not at all, 1 = a little, 2 = somewhat, 3=quite a bit, 4 = very. A higher score within each question represented increased severity of the indicated symptom. A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Meibomian Glands</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Thermalon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TrueTear™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TrueTear™</intervention_name>
    <description>Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.</description>
    <arm_group_label>TrueTear™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermalon Dry Eye Compress</intervention_name>
    <description>Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.</description>
    <arm_group_label>Thermalon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dry eye disease or Meibomian Gland Disease as evaluated by Standard Participant&#xD;
             Evaluation for Dryness (SPEED) score, Schirmer test, Tear film breakup time and other&#xD;
             applicable objective measures at the Screening and Baseline Visits.&#xD;
&#xD;
          -  Use of an artificial tear product, lid hygiene, omega-3 supplementation, antibiotics&#xD;
             for the treatment of dry eye disease or Meibomian Gland Disease within one year of the&#xD;
             Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic or recurrent epistaxis, coagulation disorders or other conditions that may&#xD;
             increase the risk of bleeding.&#xD;
&#xD;
          -  History of nasal or sinus surgery.&#xD;
&#xD;
          -  Vascularized polyp, deviated septum or severe nasal airway obstruction at the&#xD;
             Screening visit.&#xD;
&#xD;
          -  Intraocular and extraocular surgery in either eye within three months of the Screening&#xD;
             Visit or refractive surgery within twelve months of the Screening Visit.&#xD;
&#xD;
          -  Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic&#xD;
             or active implanted electronic device in the head.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>mdlasik@comcast.net</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <results_first_submitted>October 8, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2020</results_first_posted>
  <disposition_first_submitted>October 8, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>October 8, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 10, 2018</disposition_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03226769/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03226769/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thermalon</title>
          <description>Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.</description>
        </group>
        <group group_id="P2">
          <title>TrueTear™</title>
          <description>Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Thermalon</title>
          <description>Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.</description>
        </group>
        <group group_id="B2">
          <title>TrueTear™</title>
          <description>Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="12.16"/>
                    <measurement group_id="B2" value="63.8" spread="13.91"/>
                    <measurement group_id="B3" value="63.5" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Meibomian Gland Dysfunction (MGD) Impact Questionnaire Score</title>
          <description>MGD impact questionnaire includes 10 questions about impacts participant may experience associated with MGD. Question/s (Qs) 1-6 were rated on a scale of 1=no difficulty to 5=lot of difficulty. Q7 was rated on scale of 1=never to 5=all the time. If participants did not experience particular impact, they chose 0=Not applicable (NA) for Qs 1-7. Q8 was rated on scale 0-4, where 0=no time at all to 4=lot of time, Qs 9-10 were rated on scale 0-4, with 0=not at all bothered to 4=very bothered. Higher scores represented greater impact. For additional scale information see Outcome Measure section.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Computer Usage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="2.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="2.1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reading</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="2.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="B3" value="2.3" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leisure Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="2.2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="B3" value="2.3" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B2" value="1.7" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="1.5" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Driving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="2.1" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B3" value="2.0" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outdoor Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="B2" value="1.6" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="1.7" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frequency of Outdoor Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="1.8" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="B3" value="1.9" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Spent to Take Care of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B2" value="1.4" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B3" value="1.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bothered With Amount of Time Taking Care of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="0.9" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B3" value="1.1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bothered by Appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="1.2" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="1.1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MGD Symptoms Questionnaire Score</title>
          <description>MGD symptom questionnaire included 11 questions about the symptoms the participant may experience associated with MGD. The participant was asked to rate how much they experienced certain MGD symptoms and the severity of the symptoms over the past 24 hours on a scale of 0 to 4, where 0 = not at all, 1 = a little, 2 = somewhat, 3=quite a bit, 4 = very. A higher score within each question represented increased severity of the indicated symptom. For additional scale information see Outcome Measure section.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Red Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="1.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B3" value="1.2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred Vision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B2" value="1.2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B3" value="1.3" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="2.5" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B3" value="2.5" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itchy Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="1.6" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="1.9" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="1.5" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="1.5" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gritty Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="1.7" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="1.8" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Painful Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B2" value="0.9" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B3" value="0.9" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Watery Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="1.3" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="1.3" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Eyelids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.6" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B2" value="0.5" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="B3" value="0.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Eyelids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="1.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="0.9" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusty Eyelids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="1.1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="1.0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Meibomian Gland Dysfunction (MGD) Impact Questionnaire Score</title>
        <description>MGD impact questionnaire includes 10 questions about the impacts a participant may experience associated with MGD. Participants were asked to rate how much they have been affected by MGD symptoms in past 7 days. Question/s (Qs) 1-6 (computer usage, reading, leisure activities, social activities, driving and outdoor activities) were rated on a scale of 1=no difficulty to 5=a lot of difficulty. Q7 (frequency of outdoor activities) was rated on scale of 1=never to 5=all the time. If participants did not experience a particular impact, they chose 0=NA for Qs 1-7. Q8 (time spent to take care of eyes) was rated on scale 0-4, where 0=no time at all to 4=a lot of time, Qs 9-10 (bothered with amount of time taking care of eyes and bothered by appearance) were rated on scale 0-4, with 0=not at all bothered to 4=very bothered. Higher scores represented greater impact. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 0) to Day 30</time_frame>
        <population>ITT population included all randomized participants. Overall number of participants analyzed is the number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Thermalon</title>
            <description>Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.</description>
          </group>
          <group group_id="O2">
            <title>TrueTear™</title>
            <description>Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Meibomian Gland Dysfunction (MGD) Impact Questionnaire Score</title>
          <description>MGD impact questionnaire includes 10 questions about the impacts a participant may experience associated with MGD. Participants were asked to rate how much they have been affected by MGD symptoms in past 7 days. Question/s (Qs) 1-6 (computer usage, reading, leisure activities, social activities, driving and outdoor activities) were rated on a scale of 1=no difficulty to 5=a lot of difficulty. Q7 (frequency of outdoor activities) was rated on scale of 1=never to 5=all the time. If participants did not experience a particular impact, they chose 0=NA for Qs 1-7. Q8 (time spent to take care of eyes) was rated on scale 0-4, where 0=no time at all to 4=a lot of time, Qs 9-10 (bothered with amount of time taking care of eyes and bothered by appearance) were rated on scale 0-4, with 0=not at all bothered to 4=very bothered. Higher scores represented greater impact. A negative change from Baseline indicates improvement.</description>
          <population>ITT population included all randomized participants. Overall number of participants analyzed is the number of participants with data available for analyses.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Computer Usage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.86"/>
                    <measurement group_id="O2" value="-0.3" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reading</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.90"/>
                    <measurement group_id="O2" value="-0.2" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leisure Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.89"/>
                    <measurement group_id="O2" value="-0.4" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.87"/>
                    <measurement group_id="O2" value="-0.2" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Driving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.92"/>
                    <measurement group_id="O2" value="-0.2" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outdoor Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.81"/>
                    <measurement group_id="O2" value="-0.1" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frequency of Outdoor Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.69"/>
                    <measurement group_id="O2" value="-0.1" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Spent to Take Care of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.83"/>
                    <measurement group_id="O2" value="0.1" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bothered With Amount of Time Taking Care of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.01"/>
                    <measurement group_id="O2" value="0.0" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bothered by Appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.77"/>
                    <measurement group_id="O2" value="-0.1" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Computer Usage</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.9788</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reading</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.6571</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Leisure Activities</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.4710</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Activities</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.7360</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Driving</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.4999</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outdoor Activities</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.1159</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Frequency of Outdoor Activities</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.4567</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time Spent to Take Care of Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.3439</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bothered With Amount of Time Taking Care of Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.3331</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bothered by Appearance</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.4774</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in MGD Symptoms Questionnaire Score</title>
        <description>MGD symptom questionnaire included 11 questions about the symptoms the participant may experience associated with MGD. The participant was asked to rate how much they experienced certain MGD symptoms and the severity of the symptoms over the past 24 hours on a scale of 0 to 4, where 0 = not at all, 1 = a little, 2 = somewhat, 3=quite a bit, 4 = very. A higher score within each question represented increased severity of the indicated symptom. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline (Day 0) to Day 30</time_frame>
        <population>ITT population included all randomized participants. Overall number of participants analyzed is the number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Thermalon</title>
            <description>Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.</description>
          </group>
          <group group_id="O2">
            <title>TrueTear™</title>
            <description>Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MGD Symptoms Questionnaire Score</title>
          <description>MGD symptom questionnaire included 11 questions about the symptoms the participant may experience associated with MGD. The participant was asked to rate how much they experienced certain MGD symptoms and the severity of the symptoms over the past 24 hours on a scale of 0 to 4, where 0 = not at all, 1 = a little, 2 = somewhat, 3=quite a bit, 4 = very. A higher score within each question represented increased severity of the indicated symptom. A negative change from baseline indicates improvement.</description>
          <population>ITT population included all randomized participants. Overall number of participants analyzed is the number of participants with data available for analyses.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.76"/>
                    <measurement group_id="O2" value="-0.1" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred Vision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.85"/>
                    <measurement group_id="O2" value="-0.2" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.04"/>
                    <measurement group_id="O2" value="-0.5" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itchy Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.23"/>
                    <measurement group_id="O2" value="-0.3" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.77"/>
                    <measurement group_id="O2" value="-0.5" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gritty Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.99"/>
                    <measurement group_id="O2" value="-0.4" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Painful Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.87"/>
                    <measurement group_id="O2" value="-0.1" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Watery Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.20"/>
                    <measurement group_id="O2" value="-0.1" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Eyelids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.93"/>
                    <measurement group_id="O2" value="0.3" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Eyelids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.78"/>
                    <measurement group_id="O2" value="-0.1" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusty Eyelids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.75"/>
                    <measurement group_id="O2" value="-0.4" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Red Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.5457</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Blurred Vision</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.9786</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dry Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.3894</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Itchy Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.0591</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Burning Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.1818</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Gritty Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.4284</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Painful Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.1051</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Watery Eyes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.7998</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swollen Eyelids</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.1229</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Red Eyelids</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.3907</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Crusty Eyelids</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that there is no difference between the two devices, TrueTear™ and Thermalon.</non_inferiority_desc>
            <p_value>0.0336</p_value>
            <p_value_desc>Statistically significant (p &lt; 0.05) and trending significant (p &lt; 0.10) for within-group or between-group changes from baseline at Day 30. Between-group P-value was calculated using Wilcoxon rank-sum test.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 30</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Thermalon</title>
          <description>Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.</description>
        </group>
        <group group_id="E2">
          <title>TrueTear™</title>
          <description>Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA: 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area, Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

